What is the Optimal Design-Build-Test Cycle for Clinically Relevant Synthetic CAR T Cell Therapies?

Cell Syst. 2020 Sep 23;11(3):212-214. doi: 10.1016/j.cels.2020.08.017.
No abstract available

MeSH terms

  • Humans
  • Immunotherapy / methods*
  • Receptors, Antigen, T-Cell / metabolism*

Substances

  • Receptors, Antigen, T-Cell